Endocrine Metabolic

Printing and PDF export are disabled for this protected preview. Continue reading inside the DiraChart reader.

Trace DC46-23

DiraChart Clinical Reference
Protected section 23 of 25
← Document menu
Home Care · DiraChart

1. Purpose and clinical relevance

DiraChart Clinical Reference

Section NavigationPart 23 of 25PreviousNext

Normal narrative bank — stable / at-baseline

Seven upgraded normal narratives. Each shows what was assessed, the objective finding, the baseline comparison, and the skilled reason the visit required a nurse — edit to the actual visit.

N1

Glucose log in individualized range, insulin technique correct

Skilled endocrine assessment with glucose-log review. Self-monitored values 95–155 over the week, within the patient’s individualized ordered target of 80–180, without hypoglycemic events; the pattern is stable and correlates appropriately with meals and the insulin schedule. Insulin draw and injection were observed: correct dose per order, appropriate site rotation, and correct storage. The interpretation of the pattern against the individualized target and the observed correct technique confirm safe, controlled management; the monitoring schedule and hypoglycemia rescue were reinforced, with the patient return-demonstrating injection correctly (cross-reference Diabetes overlay).

N2

Stable thyroid replacement, euthyroid

Skilled assessment of a patient on levothyroxine replacement. No heat or cold intolerance, palpitations, tremor, or new fatigue; weight stable; replacement taken correctly on an empty stomach and separated from interfering medications. The absence of over- or under-treatment symptoms and confirmed adherence, evaluated against baseline and the laboratory trend, confirm the replacement dose is appropriate; the timing and adherence requirements and the symptoms to report were reinforced, with the patient verbalizing them correctly (systemic and neck exam in Neck/Thyroid).

N3

Steroid therapy monitored, no decompensation

Skilled assessment of a patient on chronic corticosteroid therapy. No signs of adrenal insufficiency (hypotension, profound weakness, nausea) or steroid excess beyond expected; glucose monitored for steroid-induced hyperglycemia and within the individualized target; the patient verbalized the stress-dose and sick-day plan. The absence of insufficiency or uncontrolled hyperglycemia and confirmed understanding of stress dosing confirm safe management; the never-stop-abruptly rule and the warning signs of adrenal crisis were reinforced with correct teach-back.

N4

Diabetic foot intact, sensation documented

Skilled assessment including the diabetic foot screen. Feet inspected and intact without lesions, fissures, or callus breakdown; footwear appropriate; protective sensation documented as reduced at the forefoot per the monofilament screen (detail in Touch/Sensation). The intact skin with a known reduced-sensation status, assessed directly, confirms the foot is at risk but currently uncompromised; daily foot inspection, proper footwear, and injury and burn prevention were reinforced, with the patient return-demonstrating a correct foot check (cross-reference Touch/Sensation and Wounds).

N5

New insulin start, technique mastered

Skilled assessment of a patient newly started on basal insulin. Reviewed the indication, dose, timing, and storage; the patient drew and injected under observation with initially uncertain but ultimately correct technique after coaching, rotating sites appropriately. Early glucose values are trending toward the individualized target without hypoglycemia. The mastery of technique on return demonstration and the early in-target trend confirm a safe insulin start; monitoring, hypoglycemia recognition and rescue, and storage were taught, with the patient and caregiver return-demonstrating correctly (cross-reference Diabetes overlay).

N6

A1c at individualized target, stable regimen

Skilled assessment of a patient with type 2 diabetes. The most recent A1c is at the individualized ordered target and the self-monitored pattern is consistent with it, without hypoglycemia; the oral and injectable regimen is adherent and tolerated. The agreement of the A1c and the home pattern with the individualized target, evaluated against baseline, confirms stable control on the current regimen; adherence, monitoring, and the parameters to report were reinforced, with the patient verbalizing the plan correctly.

N7

Hypoglycemia-prevention plan in place

Skilled assessment of a patient with prior hypoglycemia now stable. No hypoglycemic events since the plan was implemented; meals and insulin timing aligned, a rapid-acting carbohydrate and a glucagon kit are available and not expired, and the caregiver knows their use. The absence of events and the confirmed rescue readiness, compared to the prior pattern of lows, confirm the prevention plan is effective; symptom recognition, meal-insulin timing, and glucagon use were reinforced, with the caregiver return-demonstrating glucagon correctly.

Section NavigationPart 23 of 25PreviousNext